AstraZeneca
United States
256 articles with AstraZeneca
-
The company is conducting analyses to understand safety data that had been gathered prior to the pausing of the three studies, NCT04605159, NCT04980391 and NCT05229068.
-
The latest EUA adjustment was based on findings that Evusheld might not be as active against certain subvariants of Omicron, but it could be if the dosage is increased.
-
AstraZeneca progresses Ambition Zero Carbon programme with Honeywell partnership to develop next-generation respiratory inhalers
2/22/2022
AstraZeneca and Honeywell will partner to develop next-generation respiratory inhalers using the propellant HFO-1234ze, which has up to 99.9% less Global Warming Potential (GWP) than propellants currently used in respiratory medicines.
-
LYNPARZA® (olaparib) Plus Abiraterone Reduced Risk of Disease Progression or Death by 34% Versus Abiraterone in First-Line Metastatic Castration-Resistant Prostate Cancer, Regardless of Biomarker Status
2/14/2022
AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that positive results from the Phase 3 PROpel trial showed LYNPARZA in combination with abiraterone plus prednisone demonstrated a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS) versus abiraterone plus prednisone,
-
LYNPARZA® (olaparib) plus Abiraterone Reduced Risk of Disease Progression by 34% vs. Standard-of-Care in 1st-Line Metastatic Castration-Resistant Prostate Cancer
2/14/2022
LYNPARZA® (olaparib) plus Abiraterone Reduced Risk of Disease Progression by 34% vs. Standard-of-Care in 1st-Line Metastatic Castration-Resistant Prostate Cancer.
-
Clinical trials in Russia and Azerbaijan demonstrated safety of AstraZeneca and Sputnik Light vaccines combination
2/14/2022
The Russian Direct Investment Fund announce interim results of phase II clinical trials to evaluate the safety and immunogenicity of the combined use of AstraZeneca's vaccine and the first component of the Sputnik V coronavirus vaccine (Sputnik Lite).
-
Regio Biosciences Enters into License Agreement with AstraZeneca for Phase 2a Asset in Peripheral Artery Disease (PAD)
2/3/2022
Regio Biosciences (Regio), a Hibiscus BioVentures company, announced today it has entered into an exclusive license agreement with AstraZeneca to further develop REG-101, a novel therapeutic acting on reverse cholesterol transport (RCT).
-
Eplontersen granted Orphan Drug Designation in the US for transthyretin amyloidosis
1/24/2022
Eplontersen has been granted Orphan Drug Designation (ODD) in the US by the Food and Drug Administration (FDA) for the treatment of transthyretin-mediated amyloidosis, a systemic, progressive and fatal condition.
-
Enhertu Granted Priority Review in the US for Patients With HER2-Positive Metastatic Breast Cancer Treated With a Prior Anti-HER2-Based Regimen
1/17/2022
Enhertu Granted Priority Review in the US for Patients With HER2-Positive Metastatic Breast Cancer Treated With a Prior Anti-HER2-Based Regimen.
-
BenevolentAI announces 3-year collaboration expansion with AstraZeneca focused on systemic lupus erythematosus and heart failure
1/13/2022
BenevolentAI , a leading clinical-stage AI drug discovery company, has expanded its AI-driven drug discovery collaboration with AstraZeneca.
-
TEZSPIRE Now Available in the United States for the Treatment of Severe Asthma
1/13/2022
AstraZeneca and Amgen today announced TEZSPIRE™ (tezepelumab-ekko) is now available for shipment to wholesalers in the US.
-
Scorpion Therapeutics Enters Agreement with AstraZeneca to Discover, Develop and Commercialize Novel Cancer Treatments Against ‘Undruggable’ Targets
1/13/2022
Scorpion Therapeutics, Inc. today announced a collaboration with AstraZeneca (LSE/STO/NYSE: AZN) to discover, develop and commercialize precision medicines against previously hard-to-target cancer proteins, with the potential to transform oncology treatment.
-
Ovid Therapeutics Expands Epilepsy Franchise with Novel KCC2 Activators
1/3/2022
Exclusive license from AstraZeneca adds a unique candidate and a broad library of compounds to Ovid’s franchise of potential first-in-class anti-epileptic therapies.
-
EVUSHELD long-acting antibody combination retains neutralizing activity against Omicron variant in studies from Oxford and Washington Universities
12/23/2021
EVUSHELD long-acting antibody combination retains neutralizing activity against Omicron variant in studies from Oxford and Washington Universities.
-
FDA Approves TEZSPIRE™ (tezepelumab-ekko), AstraZeneca and Amgen's First-in-Class Treatment for Severe Asthma
12/22/2021
Brand Institute is proud to announce its successful partnership with AstraZeneca and Amgen in naming TEZSPIRE ™, the first and only biologic to consistently and significantly reduce asthma exacerbations in a broad population of severe asthma patients.
-
FDA APPROVES TEZSPIRE™ (TEZEPELUMAB-EKKO) IN THE U.S. FOR SEVERE ASTHMA
12/17/2021
Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved Amgen and AstraZeneca's Tezspire™ (tezepelumab-ekko) for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.
-
TEZSPIRE (tezepelumab) Approved in the US for Severe Asthma
12/17/2021
AstraZeneca and Amgen’s TEZSPIRE (tezepelumab-ekko) has been approved in the US for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma.
-
EVUSHELD long-acting antibody combination retains neutralizing activity against Omicron variant in independent FDA study
12/16/2021
AstraZeneca’s EVUSHELD (tixagevimab co-packaged with cilgavimab), a long-acting antibody combination for the prevention of COVID-19, retained neutralizing activity against the Omicron SARS-CoV-2 variant (B.1.1.529), according to new preclinical data.
-
Samsung Biologics and AstraZeneca expand strategic manufacturing partnership to include COVID-19 and cancer therapy
12/14/2021
Samsung Biologics (207940.KS), the world's leading contract development and manufacturing organization, continues its strategic biopharmaceutical manufacturing collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN).
-
FDA Issues Emergency Use Authorization For Astrazeneca's Evusheld™ (Tixagevimab Co-packaged With Cilgavimab), The First Antibody Therapy Authorized In The U.S. For Pre-exposure Prophylaxis Of COVID-19
12/10/2021
Brand Institute is proud to announce its successful partnership with AstraZeneca in developing the brand name EVUSHELD™ and assisting with the development of the nonproprietary names tixagevimab and cilgavimab, together denoting the first long-acting antibody combination authorized for emergency use by the U.S. Food and Drug Administration (FDA) for pre-exposure prevention of COVID-19.